Post-traumatic stress disorder (PTSD) is a severe mental illness characterized by increased arousal, intrusion, avoidance, and negative cognitive alterations following exposure to fatal stresses or psychological trauma. In this study, I explored the a...
Post-traumatic stress disorder (PTSD) is a severe mental illness characterized by increased arousal, intrusion, avoidance, and negative cognitive alterations following exposure to fatal stresses or psychological trauma. In this study, I explored the ameliorating effects of schizandrin on PTSD-like behaviors in PTSD model mice induced by single prolonged stress (SPS). A single dose of schizandrin (10 mg/kg, p.o.) ameliorated PTSD-like behaviors as assessed using the elevated plus-maze test, Y-maze test, tail suspension test, and fear extinction test. Using network pharmacology, I identified 6 core protein targets among 47 candidates. Molecular docking analysis further revealed that schizandrin binds most stably to the 5-HT1A receptor, a key modulator of fear and stress responses. I discovered that schizandrin normalized downstream signaling of the 5-HT1A receptor in the amygdala by modulating the PKA-CREB and PI3K-Akt- mTOR pathways. Furthermore, antagonism study confirmed the specificity of schizandrin’s action as 5-HT1A receptor agonist. These results suggest that schizandrin could be an effective treatment for PTSD via 5-HT1A receptor activation, addressing the limitations of current PTSD medications.